vs

Side-by-side financial comparison of Clearfield, Inc. (CLFD) and CRISPR Therapeutics AG (CRSP). Click either name above to swap in a different company.

CRISPR Therapeutics AG is the larger business by last-quarter revenue ($35.7M vs $34.3M, roughly 1.0× Clearfield, Inc.). Clearfield, Inc. runs the higher net margin — -1.8% vs -104.5%, a 102.8% gap on every dollar of revenue. On growth, Clearfield, Inc. posted the faster year-over-year revenue change (-3.2% vs -82.3%). Clearfield, Inc. produced more free cash flow last quarter ($-2.4M vs $-50.3M).

Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. I...

CLFD vs CRSP — Head-to-Head

Bigger by revenue
CRSP
CRSP
1.0× larger
CRSP
$35.7M
$34.3M
CLFD
Growing faster (revenue YoY)
CLFD
CLFD
+79.1% gap
CLFD
-3.2%
-82.3%
CRSP
Higher net margin
CLFD
CLFD
102.8% more per $
CLFD
-1.8%
-104.5%
CRSP
More free cash flow
CLFD
CLFD
$47.9M more FCF
CLFD
$-2.4M
$-50.3M
CRSP

Income Statement — Q1 FY2026 vs Q4 FY2024

Metric
CLFD
CLFD
CRSP
CRSP
Revenue
$34.3M
$35.7M
Net Profit
$-614.0K
$-37.3M
Gross Margin
33.2%
Operating Margin
-5.3%
-181.0%
Net Margin
-1.8%
-104.5%
Revenue YoY
-3.2%
-82.3%
Net Profit YoY
67.8%
-141.8%
EPS (diluted)
$-0.04
$-0.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLFD
CLFD
CRSP
CRSP
Q4 25
$34.3M
Q3 25
$23.4M
Q2 25
$49.9M
Q1 25
$47.2M
Q4 24
$29.7M
$35.7M
Q3 24
$5.6M
Q2 24
$48.8M
Q1 24
$36.9M
Net Profit
CLFD
CLFD
CRSP
CRSP
Q4 25
$-614.0K
Q3 25
$-9.1M
Q2 25
$1.6M
Q1 25
$1.3M
Q4 24
$-1.9M
$-37.3M
Q3 24
Q2 24
$-447.0K
Q1 24
$-5.9M
Gross Margin
CLFD
CLFD
CRSP
CRSP
Q4 25
33.2%
Q3 25
53.2%
Q2 25
30.5%
Q1 25
30.1%
Q4 24
29.2%
Q3 24
Q2 24
21.9%
Q1 24
7.7%
Operating Margin
CLFD
CLFD
CRSP
CRSP
Q4 25
-5.3%
Q3 25
10.3%
Q2 25
3.0%
Q1 25
0.6%
Q4 24
-6.9%
-181.0%
Q3 24
Q2 24
-4.7%
Q1 24
-26.4%
Net Margin
CLFD
CLFD
CRSP
CRSP
Q4 25
-1.8%
Q3 25
-38.8%
Q2 25
3.2%
Q1 25
2.8%
Q4 24
-6.4%
-104.5%
Q3 24
Q2 24
-0.9%
Q1 24
-16.0%
EPS (diluted)
CLFD
CLFD
CRSP
CRSP
Q4 25
$-0.04
Q3 25
$-0.65
Q2 25
$0.11
Q1 25
$0.09
Q4 24
$-0.13
$-0.41
Q3 24
Q2 24
$-0.04
Q1 24
$-0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLFD
CLFD
CRSP
CRSP
Cash + ST InvestmentsLiquidity on hand
$96.4M
$1.9B
Total DebtLower is stronger
Stockholders' EquityBook value
$249.7M
$1.9B
Total Assets
$268.1M
$2.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLFD
CLFD
CRSP
CRSP
Q4 25
$96.4M
Q3 25
$106.0M
Q2 25
$117.2M
Q1 25
$112.0M
Q4 24
$113.0M
$1.9B
Q3 24
$129.0M
Q2 24
$123.8M
Q1 24
$142.9M
Total Debt
CLFD
CLFD
CRSP
CRSP
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$2.2M
Q2 24
$2.1M
Q1 24
Stockholders' Equity
CLFD
CLFD
CRSP
CRSP
Q4 25
$249.7M
Q3 25
$256.2M
Q2 25
$264.5M
Q1 25
$265.9M
Q4 24
$267.4M
$1.9B
Q3 24
$275.8M
Q2 24
$274.6M
Q1 24
$279.2M
Total Assets
CLFD
CLFD
CRSP
CRSP
Q4 25
$268.1M
Q3 25
$306.2M
Q2 25
$314.7M
Q1 25
$310.9M
Q4 24
$303.2M
$2.2B
Q3 24
$315.3M
Q2 24
$318.1M
Q1 24
$315.4M
Debt / Equity
CLFD
CLFD
CRSP
CRSP
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.01×
Q2 24
0.01×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLFD
CLFD
CRSP
CRSP
Operating Cash FlowLast quarter
$-1.4M
$-50.0M
Free Cash FlowOCF − Capex
$-2.4M
$-50.3M
FCF MarginFCF / Revenue
-7.1%
-140.9%
Capex IntensityCapex / Revenue
2.9%
0.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-325.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLFD
CLFD
CRSP
CRSP
Q4 25
$-1.4M
Q3 25
Q2 25
$7.9M
Q1 25
$3.0M
Q4 24
$7.2M
$-50.0M
Q3 24
$22.2M
Q2 24
$4.0M
Q1 24
$-5.7M
Free Cash Flow
CLFD
CLFD
CRSP
CRSP
Q4 25
$-2.4M
Q3 25
Q2 25
$7.5M
Q1 25
$654.0K
Q4 24
$5.1M
$-50.3M
Q3 24
$18.2M
Q2 24
$2.8M
Q1 24
$-7.7M
FCF Margin
CLFD
CLFD
CRSP
CRSP
Q4 25
-7.1%
Q3 25
Q2 25
15.1%
Q1 25
1.4%
Q4 24
17.1%
-140.9%
Q3 24
323.0%
Q2 24
5.8%
Q1 24
-20.8%
Capex Intensity
CLFD
CLFD
CRSP
CRSP
Q4 25
2.9%
Q3 25
2.0%
Q2 25
0.8%
Q1 25
5.1%
Q4 24
7.0%
0.7%
Q3 24
71.4%
Q2 24
2.5%
Q1 24
5.3%
Cash Conversion
CLFD
CLFD
CRSP
CRSP
Q4 25
Q3 25
Q2 25
4.93×
Q1 25
2.30×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLFD
CLFD

Segment breakdown not available.

CRSP
CRSP

Collaboration Revenue$35.0M98%
Grant$2.3M6%

Related Comparisons